Harpreet Singh-Jasuja
Founder en IMMATICS N.V. .
Fortuna: 13 M $ al 31/03/2024
Perfil
Harpreet Singh-Jasuja is the founder of Immatics Biotechnologies GmbH, founded in 2000, where he currently holds the title of Chief Executive Officer.
He is also the founder of Immatics US, Inc., founded in 2015, where he currently holds the title of President & Chief Executive Officer.
Additionally, he is the founder of Immatics NV, founded in 2000, where he currently holds the title of Chief Executive Officer, Executive Director & MD.
Dr. Singh-Jasuja has an education background from Eberhard Karls Universität Tübingen, where he obtained undergraduate and doctorate degrees.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
IMMATICS N.V.
1.24% | 31/01/2024 | 1 276 988 ( 1.24% ) | 13 M $ | 31/03/2024 |
Cargos activos de Harpreet Singh-Jasuja
Empresas | Cargo | Inicio |
---|---|---|
IMMATICS N.V. | Founder | 01/01/2000 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Chief Executive Officer | 01/01/2000 |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Chief Executive Officer | 01/06/2015 |
Formación de Harpreet Singh-Jasuja.
Eberhard Karls Universität Tübingen | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
IMMATICS N.V. | Health Technology |
Empresas privadas | 2 |
---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Health Technology |
- Bolsa de valores
- Insiders
- Harpreet Singh-Jasuja